Skip to main content
. 2022 Jun 11;11(6):1149. doi: 10.3390/antiox11061149

Figure 15.

Figure 15

(A–K): Histological changes in prostate lobes (immunostained prostate sections against (PARP1)): Microscopic pictures representing sections of comparable regions in ventral and lateral lobes of the control group (A,B), (BPH) group (C,D), finasteride group (E,F), O. majorana 250 group (G,H) and O. majorana 500 group (I,J). Black arrows demonstrate positive epithelial immunoreactivity. IHC counterstained with Mayer’s hematoxylin. X: 100 bar 100 μm (low magnification) and X: 400 bar 50 μm (high magnification). (K) A graph showing the Allred scoring system. Values are expressed as mean ± SD (n = 8). 0–1 (negative), 2–3 (mild), 4–6 (moderate) and 7–8 (strong). *** p < 0.001 vs. BPH (model) group and ∆∆∆ p < 0.001, vs. control for ventral lobe, ### p < 0.001 vs. BPH (model) group and ΦΦ p < 0.01, ΦΦΦ p < 0.001 vs. control for lateral lobe.